241 related articles for article (PubMed ID: 16155368)
21. Is dermolipectomy effective in improving insulin action and lowering inflammatory markers in obese women?
Rizzo MR; Paolisso G; Grella R; Barbieri M; Grella E; Ragno E; Grella R; Nicoletti G; D'Andrea F
Clin Endocrinol (Oxf); 2005 Sep; 63(3):253-8. PubMed ID: 16117810
[TBL] [Abstract][Full Text] [Related]
22. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Horm Metab Res; 2010 Jan; 42(1):8-13. PubMed ID: 19735057
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C.
Antoniades C; Tousoulis D; Tountas C; Tentolouris C; Toutouza M; Vasiliadou C; Tsioufis C; Toutouzas P; Stefanadis C
Diabet Med; 2004 Jun; 21(6):552-8. PubMed ID: 15154938
[TBL] [Abstract][Full Text] [Related]
24. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
25. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab.
Di Rocco P; Manco M; Rosa G; Greco AV; Mingrone G
Obes Res; 2004 Apr; 12(4):734-9. PubMed ID: 15090644
[TBL] [Abstract][Full Text] [Related]
26. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.
Klein S; Fontana L; Young VL; Coggan AR; Kilo C; Patterson BW; Mohammed BS
N Engl J Med; 2004 Jun; 350(25):2549-57. PubMed ID: 15201411
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.
Fontaine-Bisson B; Wolever TM; Chiasson JL; Rabasa-Lhoret R; Maheux P; Josse RG; Leiter LA; Rodger NW; Ryan EA; El-Sohemy A
Metabolism; 2007 May; 56(5):649-55. PubMed ID: 17445540
[TBL] [Abstract][Full Text] [Related]
28. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.
Natali A; Toschi E; Baldeweg S; Ciociaro D; Favilla S; Saccà L; Ferrannini E
Diabetes; 2006 Apr; 55(4):1133-40. PubMed ID: 16567539
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
30. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index.
Ruge T; Lockton JA; Renstrom F; Lystig T; Sukonina V; Svensson MK; Eriksson JW
Metabolism; 2009 Jun; 58(6):860-6. PubMed ID: 19375766
[TBL] [Abstract][Full Text] [Related]
31. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance.
Monzillo LU; Hamdy O; Horton ES; Ledbury S; Mullooly C; Jarema C; Porter S; Ovalle K; Moussa A; Mantzoros CS
Obes Res; 2003 Sep; 11(9):1048-54. PubMed ID: 12972674
[TBL] [Abstract][Full Text] [Related]
32. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
[TBL] [Abstract][Full Text] [Related]
33. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.
Blüher M; Fasshauer M; Tönjes A; Kratzsch J; Schön MR; Paschke R
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):534-7. PubMed ID: 16235156
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
35. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
[TBL] [Abstract][Full Text] [Related]
36. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
37. Altered tumor necrosis factor alpha release from mononuclear cells of obese reproductive-age women during hyperglycemia.
González F; Minium J; Rote NS; Kirwan JP
Metabolism; 2006 Feb; 55(2):271-6. PubMed ID: 16423637
[TBL] [Abstract][Full Text] [Related]
38. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory cytokines in insulin-treated patients with type 2 diabetes.
Mavridis G; Souliou E; Diza E; Symeonidis G; Pastore F; Vassiliou AM; Karamitsos D
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):471-6. PubMed ID: 17976964
[TBL] [Abstract][Full Text] [Related]
40. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
